While certain splicing events, including those validated in our study (ATM, CHD1L, DDX11, EXO1, FAN1, PNKP, SLX4) are common to bulk tumour cells and BCSCs, numerous events are notably enriched in BCSCs, both providing new opportunities to identify combination PRMT5 inhibitor approaches that maximise the potential of PRMT5-directed therapy. This evidence concerns the gene CHD1L and neoplasm.